



University of Dundee

Whole-exome sequencing improves mutation detection in a diagnostic epidermolysis bullosa laboratory

Takeichi, T.; Liu, L.; Fong, K.; Ozoemena, L.; McMillan, J. R.; Salam, A.

Published in:
British Journal of Dermatology

DOI:
[10.1111/bjd.13190](https://doi.org/10.1111/bjd.13190)

Publication date:
2015

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Takeichi, T., Liu, L., Fong, K., Ozoemena, L., McMillan, J. R., Salam, A., Campbell, P., Akiyama, M., Mellerio, J. E., McLean, W. H. I., Simpson, M. A., & McGrath, J. A. (2015). Whole-exome sequencing improves mutation detection in a diagnostic epidermolysis bullosa laboratory. *British Journal of Dermatology*, 172(1), 94-100. <https://doi.org/10.1111/bjd.13190>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

"This is the peer reviewed version of the following article:

Takeichi, T., Liu, L., Fong, K., Ozoemena, L., McMillan, J. R., Salam, A., Campbell, P., Akiyama, M., Mellerio, J. E., McLean, W. H. I., Simpson, M. A., & McGrath, J. A. (2015). Whole-exome sequencing improves mutation detection in a diagnostic epidermolysis bullosa laboratory. *British Journal of Dermatology*, 172(1), 94-100. , which has been published in final form at <https://doi.org/10.1111/bjd.13190>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions."



Whole-exome sequencing improves mutation detection in a diagnostic epidermolysis bullosa laboratory

Journal:	<i>British Journal of Dermatology</i>
Manuscript ID:	BJD-2014-0775.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Takeichi, Takuya; King's College London, St John's Institute of Dermatology; Nagoya University Graduate School of Medicine, Dermatology Liu, Lu; St Thomas' Hospital, Viapath Fong, Kenneth; King's College London, St John's Institute of Dermatology Ozoemena, Linda; St Thomas' Hospital, Viapath McMillan, James; St Thomas' Hospital, Viapath Salam, Amr; King's College London, St John's Institute of Dermatology Campbell, Patrick; King's College London, St John's Institute of Dermatology; Hull York Medical School, Akiyama, Masashi; Nagoya University Graduate School of Medicine, Dermatology Mellerio, Jemima; King's College London, St John's Institute of Dermatology; Guy's and St Thomas' NHS Foundation Trust, St John's Dermatology McLean, Irwin; University of Dundee, Dermatology and Genetic Medicine Simpson, Michael; King's College London, Department of Medical and Molecular Genetics McGrath, John; King's College London, St John's Institute of Dermatology; University of Dundee, Dermatology and Genetic Medicine
Keywords:	DNA, mutation, epidermolysis bullosa, next generation sequencing

Original article

BJD-2014-0775.R1

**Whole-exome sequencing improves mutation detection
in a diagnostic epidermolysis bullosa laboratory**

Running title: Whole-exome sequencing for EB diagnostics

Manuscript word count: 3,066

Number of Figures: 0

Number of Tables: 1

T. Takeichi^{1,2}, L. Liu³, K. Fong¹, L. Ozoemena³, J.R. McMillan³, A. Salam¹, P. Campbell^{1,4}, M. Akiyama², J.E. Mellerio^{1,5}, W.H.I. McLean,⁷ M.A. Simpson⁶, J.A. McGrath^{1,7}

¹St John's Institute of Dermatology, King's College London (Guy's Campus), London UK;

²Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya,

Japan; ³Viapath, St Thomas' Hospital, London, UK; ⁴Hull York Medical School, York, North

Yorkshire UK; ⁵St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation

Trust, London UK; ⁶Department of Medical and Molecular Genetics, King's College London

(Guy's Campus); ⁷Dermatology and Genetic Medicine, University of Dundee, Dundee, UK

1
2
3
4 **Correspondence:** John McGrath, Dermatology Research Laboratories, Floor 9 Tower Wing,
5
6 Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. Tel 44-20-71886409; Fax 44-20-
7
8 71888050; E-mail: john.mcgrath@kcl.ac.uk
9
10

11
12
13 **Funding sources:** DebRA UK; NIHR; The Wellcome Trust
14
15

16
17
18 **Conflict of interest:** The authors declare no conflict(s) of interest
19
20

21
22
23 **Key words:** whole-exome sequencing, diagnosis, mutation, epidermolysis bullosa
24
25

26 27 **What's already known about this topic?** 28

- 29
30 • Skin microscopy and Sanger sequencing are useful techniques for the accurate
31
32 diagnosis of specific subtypes of EB.
33
- 34
35 • The specificity and sensitivity of these current diagnostic tools is good although some
36
37 cases of EB elude a precise laboratory diagnosis and the work involved is often time-
38
39 consuming, labour-intensive and expensive.
40
- 41
42 • There is a need to refine and improve diagnostics for EB.
43
44
45

46 47 **What does this study add?** 48

- 49
50 • Whole-exome sequencing with bioinformatics support can identify mutations in
51
52 cases of EB for which current diagnostic techniques fall short.
53
- 54
55 • Whole-exome sequencing has the potential to lessen the need for diagnostic skin
56
57 biopsies in EB, as well as reducing laboratory costs.
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- The adoption of whole-exome sequencing into routine laboratory EB diagnostics, however, still requires a reduction in the time needed for both sample processing and data interrogation to match current diagnostic tests for EB.

For Peer Review

ABSTRACT

Background: Subtypes of inherited epidermolysis bullosa (EB) vary significantly in their clinical presentation and prognosis. Establishing an accurate diagnosis is important for genetic counselling and patient management. Current approaches in EB diagnostics involve skin biopsy for immunohistochemistry and transmission electron microscopy, as well as Sanger sequencing of candidate genes. Although informative in most cases, this approach can be expensive, laborious and may fail to identify pathogenic mutations in ~15% of cases.

Objective: Next generation DNA sequencing (NGS) technologies offer a fast and efficient complementary diagnostic strategy, but the value of NGS in EB diagnostics has yet to be explored. The aim of this study was to undertake whole-exome sequencing (WES) in 9 cases of EB in which established diagnostic methods failed to make a genetic diagnosis.

Methods: Whole-exome capture was performed using genomic DNA from each case of EB followed by massively parallel sequencing. Resulting reads were mapped to the human genome reference hg19. Potentially pathogenic mutations were subsequently confirmed by Sanger sequencing.

Results: Analysis of WES data disclosed biallelic pathogenic mutations in each case, with all mutations occurring in known EB genes (*LAMB3*, *PLEC*, *KIND1* and *COL7A1*). This study demonstrates that NGS can improve diagnostic sensitivity in EB compared to current laboratory practice.

Conclusions: With appropriate diagnostic platforms and bioinformatics support, WES is likely to increase mutation detection in cases of EB and improve EB diagnostic services, although skin biopsy remains an important diagnostic investigation in current clinical practice.

INTRODUCTION

Epidermolysis bullosa (EB) constitutes a diverse group of genodermatoses characterized by trauma-induced skin fragility, blisters and erosions.¹ Currently divided into 4 main subtypes (EB simplex, junctional EB, dystrophic EB and Kindler syndrome) based on the level of blister formation at or close to the dermal-epidermal junction (DEJ), the molecular pathology of EB now involves mutations in 18 genes.^{1,2} Over the last 20 years, international consensus group meetings have been held, most recently in 2013,¹ to revise and update the diagnosis and classification of EB. New forms of EB have been added, some disease names have been changed, and recommendations have been made about the laboratory diagnosis of EB.¹

Currently, the diagnosis of most cases of EB involves a skin biopsy. Typically, skin sections are stained with a panel of basement membrane zone antibodies and viewed by immunofluorescence microscopy (IFM). In many autosomal recessive forms of EB, the inherent loss-of-function mutations are likely to lead to a reduction or absence of immunolabelling for one particular protein, thus identifying the candidate gene for Sanger sequencing (SS).³⁻⁵ In autosomal dominant forms of EB (and some autosomal recessive cases), however, IFM may not show clear differences from normal control skin, and further clues might be sought from transmission electron microscopy (TEM).⁶ The overall objective is to determine which gene(s) to then investigate by SS. For the known EB genes, pairs of primers are designed to amplify individual exons and flanking introns. Polymerase chain reaction (PCR) products (typically 200-350 base pairs in size) are then individually examined by SS. PCR amplification protocols and primer pair sequences have been published for all known EB genes and similar protocols and reagents have been adopted into laboratory practice for diagnosing EB throughout the world. Several of the EB genes contain numerous

1
2
3
4 exons: for example, *COL7A1* (encoding type VII collagen, which is mutated in DEB) contains
5
6 118 exons and >70 PCR primer pairs are necessary for amplification of all exons and flanking
7
8 introns.^{7,8} To amplify all 18 genes implicated in the different forms of EB currently requires
9
10 >400 primer pairs for genomic DNA analysis, hence the almost inevitable need for candidate
11
12 gene clues from skin biopsies.
13
14

15
16 In 2004, we established a national diagnostic service for EB in the UK (designated
17
18 The Robin Eady National Diagnostic Epidermolysis Bullosa Laboratory, and based at St
19
20 Thomas' Hospital, London, UK). The approach to diagnosis in cases of EB has involved IFM,
21
22 TEM and SS, as outlined above, but in a number of cases (perhaps ~15% of >1500 cases)
23
24 these methods have failed to reveal any pathogenic mutations. Some of these cases may
25
26 reflect erroneous clinical diagnoses by the referring clinicians but undoubtedly, technical
27
28 limitations have also contributed to the sensitivity of current diagnostic methods.
29
30
31

32
33 One new technology that could potentially improve sensitivity in EB diagnostics is
34
35 next-generation sequencing (NGS), in which the whole genome or a portion thereof is
36
37 sequenced.^{9,10} NGS has proven very useful for identifying novel genetic variants responsible
38
39 for Mendelian disorders, including a new form of EBS.¹¹ However, although informative in a
40
41 research setting, the diagnostic utility of NGS remains unclear.¹²⁻¹⁴ To assess the potential
42
43 impact of NGS on EB diagnostics, we undertook WES and bioinformatic data analysis on 9
44
45 autosomal recessive cases of EB in which current diagnostic strategies had failed to identify
46
47 one or both of the pathogenic mutations.
48
49
50

51 52 53 **Methodology**

54 55 *Cases for study*

56
57
58
59
60

1
2
3
4 The 9 cases, with a clinical diagnosis of EB, that were selected for study were all routine
5
6 diagnostic cases referred to the National Diagnostic EB Laboratory between 2008 and 2013
7
8 for which skin biopsy analysis and SS had failed to identify pathogenic mutations.
9

10 11 12 13 *Whole-exome sequencing*

14
15 Whole-exome capture was performed by in-solution hybridization using the SureSelect All
16
17 Exon 50Mb Version 4.0 (Agilent) followed by massively parallel sequencing with 100-bp
18
19 paired-end reads on the HiSeq2000 platform (Illumina). Resulting reads were mapped to
20
21 the human genome reference hg19 using the novoalign (Novocraft Technologies Sdn Bhd,
22
23 Selangor, Malaysia) alignment tool. Variant calling was undertaken at the individual sample
24
25 level with the Samtools mpileup utility.¹⁵ Resulting variant calls were filtered with the
26
27 bcftools, filtered for a minimum coverage (calls with <4 reads filtered) and hard filtered for
28
29 quality (variant with quality <20 filtered from further analysis). This high quality call set was
30
31 then annotated with respect to the genes, and consequences on protein sequence and/or
32
33 splicing with the Annovar tool.¹⁶ Further annotation regarding previously reported
34
35 observation of specific variants and estimated population frequencies was achieved through
36
37 further rounds of Annovar annotation against dbSNP137, population frequency estimates
38
39 from 1000 Genomes project <http://www.1000genomes.org/>, NHLBI GO Exome Sequencing
40
41 Project (ESP) (<https://esp.gs.washington.edu/drupal/>), and ~1000 control exomes that have
42
43 been processed through the same bioinformatics analysis pipeline. The exome data on all
44
45 cases was deemed to be of very high quality. Over 8.6 gigabases of mappable sequence data
46
47 was generated, such that >90% of the coding bases of the exome defined by the GENCODE
48
49 Project were represented by at least 20 reads.
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Case 1: Generalized intermediate JEB with elusive mutation in LAMB3

A 58-year-old white male had a clinical diagnosis of generalized intermediate JEB (previously known as non-Herlitz JEB)¹ characterized by life-long trauma-induced blistering and erosions (illustrated on the lower limbs in Figure 1), nail loss/dystrophy and some hair loss, along with two separate squamous cell carcinomas. Previous skin biopsy had shown a lamina lucida plane of cleavage by antigen mapping and markedly reduced intensity immunolabelling for laminin-332. SS of *LAMA3*, *LAMB3*, *LAMC2*, and subsequently *COL17A1*, *ITGA6* and *ITGB4*, however, did not reveal any mutations. By WES, we identified 236 novel heterozygous and 20 novel homozygous variants in his genomic DNA (see Table 1), including a homozygous 2-bp deletion mutation c.1587_1588delAG (p.Thr529Thrfs*6) in exon 13 of *LAMB3*, which was then verified by repeat SS. This deletion occurred within a ~4.7MB block of homozygosity. The mutation has been reported previously and shown to result in skipping of downstream exon 14,¹⁷ which we were also able to verify by reverse-transcriptase PCR using RNA extracted from the patient's skin (data not shown). Typically, skipping of exon 14 would be out-of-frame but with the addition of the 2-bp deletion in exon 13, the combined deletion is in-frame. This case shows that WES can offer a more sensitive approach in identifying mutations in *LAMB3*, but in addition, the findings question the current paradigm for genotype-phenotype correlation as this mutation would usually be expected to result in severe generalised JEB (previously referred to as Herlitz JEB).¹ The WES

1
2
3
4 findings also stress the need for further studies at RNA and protein levels in some cases of
5
6 EB.
7
8
9

10
11 **Case 2: Mild acral blistering, nail dystrophy and hypotonia with a mutation in a different**
12
13 **plectin isoform**
14

15 An 18-year-old Pakistani male presented with mild blistering, developmental delay and
16 hypotonia. A history of consanguinity supported autosomal recessive inheritance. IFM
17 revealed a complete absence of plectin immunostaining, supporting biallelic loss-of-
18 function mutations in *PLEC*. However, no mutation in *PLEC* was identified on SS. Given the
19 proposed mode of inheritance and rarity of this phenotype our hypothesis was that the
20 disease causing variant would be novel and homozygous. By WES we identified 454
21 heterozygous and 54 homozygous novel variants (Table 1). The filtered variant list
22 generated after WES included a novel frameshift mutation (c.92_93insG) in exon 1 of a
23 plectin isoform previously unlinked with EB (transcript accession number: AF330791).
24 Notably, only the U53204 plectin transcript is routinely sequenced during our mutation
25 screening practice. We made new genomic primers to span this mutation and confirmed its
26 presence on SS. The mutation identified by WES was located in a plectin isoform not
27 previously thought to be expressed in skin; we have since modified our *PLEC* screening
28 protocol accordingly.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Cases 3 and 4: Kindler syndrome with elusive *KIND1* mutations**
52

53 An 18-year-old Turkish male (case 3) had a history of trauma-induced blisters from early life
54 with the development of some photosensitivity and poikiloderma in light-exposed sites
55
56
57
58
59
60

1
2
3
4 during infancy and childhood. An unrelated case, an 8-year-old Indian boy (case 4), had acral
5 blistering from the first week of life, as well as photosensitivity, palmoplantar skin
6 thickening, poikiloderma and a urethral stricture/stenosis. SS of *KIND1* failed to reveal any
7 mutations in either subject. However, in the Turkish case, WES revealed 398 novel variants
8 (393 heterozygous and 5 homozygous; see Table 1), including compound heterozygous
9 mutations in *KIND1* (c.1811G>A, p.Trp604*; c.614G>A, p.Trp205*). The mutation p.Trp604*
10 is novel, whereas p.Trp205* has been reported previously.¹⁸ SS of *KIND1* failed to reveal any
11 mutations in case 4, but WES revealed 553 novel variants (541 heterozygous and 12
12 homozygous; see Table 1), which included compound known heterozygous donor splice site
13 mutations, c.1718+2T>C, and c.384_385+2del4 in *KIND1*.^{19,20} All 4 mutations were
14 confirmed in genomic DNA by repeat SS using new primers spanning the mutations. WES
15 was therefore shown to be a sensitive means of identifying existing and new *KIND1/FERMT1*
16 mutations in Kindler syndrome.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 ***Case 5: Clinically mild blistering with DST-e identified as incorrect candidate gene by IFM***

38 A 21-year-old white male had mild generalized skin fragility since early life: most of the
39 blistering was acral. IFM showed a complete absence of immunostaining for the 230-kDa
40 bullous pemphigoid antigen (BP230) but no other major differences from control skin. SS of
41 *DST-e* (that encodes BP230), however, failed to identify any pathogenic mutations.
42 Surprisingly, among 181 heterozygous and 3 homozygous novel variants identified by WES
43 (Table 1), we identified compound heterozygous mutations in a different basement
44 membrane zone gene, *COL7A1*. The mutations were c.793C>T (p.Gln265*) and c.6005G>A
45 (p.Arg2002His). These mutations in *COL7A1* were confirmed by SS and both parents were
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 shown to be respective carriers of one of the two mutations identified. Neither of these two
5
6 mutations has been reported previously. Compound heterozygosity for this
7
8 nonsense/missense combination of mutations in type VII collagen would be expected to
9
10 lead to recessive dystrophic epidermolysis bullosa (RDEB). In this case, WES revised the
11
12 clinical diagnosis from EBS to RDEB, although why the IFM only revealed an abnormality in
13
14 BP230 is not known.
15
16

17
18
19
20
21 ***Case 6: Missed COL7A1 mutation due to polymorphism in primer sequence***

22
23 A new-born white British male presented with generalized skin blistering in whom skin
24
25 biopsy revealed a complete absence of type VII collagen at the DEJ, consistent with a
26
27 diagnosis of severe generalised RDEB (Figure 2). Screening of COL7A1 by SS revealed one
28
29 heterozygous mutation in exon 7, c.904G>T (p.Glu302*), but no second mutation. By WES,
30
31 among 657 heterozygous and 24 homozygous novel variants (Table 1), however, a second
32
33 mutant COL7A1 allele was identified: a heterozygous glycine substitution, c.7505G>A
34
35 (p.Gly2502Glu), in exon 99. Neither of these mutations has been reported previously but
36
37 both are typical of the type of gene pathology that is found in RDEB. The reason why the
38
39 second mutation was missed by SS was because we subsequently identified a single
40
41 nucleotide polymorphism in intron 99-100, rs6781283, which is located within the reverse
42
43 primer used to amplify this exon and flanking introns. This polymorphism is likely to have
44
45 prevented primer annealing and, therefore, the deleterious allele would not have been
46
47 amplified during PCR. New primers were designed and the heterozygous glycine substitution
48
49 was subsequently detected by SS. This finding has important implications for the optimal
50
51 design of working primers in gene amplification and SS.
52
53
54
55
56
57
58
59
60

Cases 7-9: Elusive second allele COL7A1 mutations in RDEB

A 27-year-old white British woman (case 7) with lifelong trauma-induced blistering and nail dystrophy had a clinical diagnosis of DEB, possibly localized RDEB or *de novo* dominant DEB, since no other family members were affected. Screening of *COL7A1* by SS revealed a known single heterozygous mutation, c.4027C>T (p.Arg1343*) in exon 34. This finding indicated a diagnosis of RDEB but no second mutation was found. However, WES identified 208 heterozygous and 9 homozygous novel variants (Table 1) that revealed a second heterozygous mutation, c.8676G>A (p.Trp2892*), in exon 117 of *COL7A1*. This second mutation, which has not been reported previously, occurs close to the 3' end of the gene and probably accounts for the relatively milder RDEB phenotype.

A 26-year-old Pakistani man (case 8) had clinical features of severe generalized RDEB, with marked trauma-induced skin fragility, hand contractures, neck scarring, and oesophageal stenoses. SS of *COL7A1* revealed a single previously unreported heterozygous mutation c.3630_3631insC (p.Gln1211Profs*8) but no identifiable second loss-of function mutation. However, WES disclosed 618 heterozygous and 20 homozygous novel variants (Table 1), including a second heterozygous mutation, c.520G>A (p.Gly174Arg) in exon 4 of *COL7A1*. This missense mutation within the NC-1 domain of type VII collagen has been reported previously in RDEB and shown to cause aberrant splicing.²¹

A 61-year-old white British woman (case 9) had lifelong mild, predominantly acral blistering. Two siblings were similarly affected and all were thought to have a mild form of RDEB. SS of *COL7A1* revealed a single heterozygous mutation, c.1732C>T (p.Arg578*) in exon 13. The two siblings were also carriers of this mutation, which is known to be a

1
2
3
4 common recurrent loss-of-function mutation in *COL7A1* in the UK and northern Europe.²²
5
6 No second mutation, however, was identified by SS. In contrast, WES identified 207 novel
7
8 heterozygous and 7 homozygous variants, including a second mutant allele, c.2126T>C
9
10 (p.Val709Ala), in exon 16 of *COL7A1*, which was also present in both siblings but not in the
11
12 exome sequences from >900 ethnically matched controls. This mutation is likely to cause
13
14 subtle disruption to the function of type VII collagen, given the mild phenotype in this family.
15
16 The WES data thus expand genotype-phenotype correlation by implicating a further non-
17
18 glycine missense mutation in the pathophysiology of RDEB.
19
20
21
22
23
24

25 DISCUSSION

26
27 In these 9 cases of EB, WES proved to be highly informative in identifying the pathogenic
28
29 mutations. In 6 of these cases (1, 3, 4, 7, 8, 9), the mutations were missed by initial SS – not
30
31 because of human error, but rather due to the well-known variable peak heights associated
32
33 with current SS chemical labelling of DNA that can lead to imprecision in interpreting
34
35 sequence traces. Review of the original sequence traces indicated either subtle changes in
36
37 peak heights or equivocal findings, although repeat SS with close attention to the
38
39 nucleotides implicated by WES did reveal the presence of the mutations. In case 5, it is
40
41 uncertain why the IFM showed a lack of BP230 immunostaining when the pathogenic
42
43 mutations were in type VII collagen – but this highlighted the potential fallibility of using IFM
44
45 to determine the candidate gene for SS in cases of EB, even though this approach has
46
47 proved to be highly informative, particularly in severe recessive forms of EB. In this case, the
48
49 relatively mild clinical features were thought to be consistent with other cases that have
50
51 demonstrated pathogenic mutations in *DST-e*,²³ and thus the combination of
52
53
54
55
56
57
58
59
60

1
2
3
4 clinicopathological information unfortunately led to erroneous sequencing of *DST-e*. Only
5
6 the finding of *COL7A1* mutations using WES provided the true molecular pathology and
7
8 helped correct the clinical diagnosis from autosomal recessive EB simplex to one of mild
9
10 RDEB. For the other 2 cases, however, WES was fundamentally important in identifying the
11
12 molecular basis of the EB. In case 2, the clinicopathological evidence pointed to plectin
13
14 pathology but SS did not disclose any mutations in *PLEC*, at least using established
15
16 sequencing protocols and primers. However, WES identified a recessive homozygous
17
18 mutation in a different isoform of *PLEC*. We subsequently used reverse transcriptase PCR to
19
20 confirm that this isoform was indeed expressed in skin (data not shown) and thereafter
21
22 modified our PCR approach for SS of *PLEC* for screening future cases. In case 6, the failure of
23
24 SS lay in the fact that there was a non-pathogenic polymorphism within one of the PCR
25
26 primers that led to failure of amplification of that *COL7A1* allele, which in this case
27
28 happened to contain one of the pathogenic mutations. We have previously encountered
29
30 this failure to amplify one allele for exon 23 of *LAMB3* in cases of junctional EB which led to
31
32 a redesign of the genomic DNA PCR primers,²⁴ and our new findings for *COL7A1* have also
33
34 prompted us to redesign primers for exon 98 and 99 and flanking introns. The primers we
35
36 recommend are: 5'-cgtatgtcttactccacagc (intron 97) and 5'-acccttagtcctgcactc (intron 99).
37
38 Given that the primer pair we were using was the same as that initially suggested in a widely
39
40 cited *COL7A1* amplification protocol,⁷ our data should encourage others involved in *COL7A1*
41
42 mutation analysis by SS to review their choice of PCR primers for these particular exons.
43
44
45
46
47
48
49
50

51 Our study is not a direct comparison between our existing diagnostic approach for
52
53 EB and NGS. Rather, this analysis was meant as a first step in determining whether WES
54
55 might improve diagnostic sensitivity in EB in being able to identify mutations that have
56
57
58
59
60

1
2
3
4 proved elusive using current SS approaches. Unequivocally, WES is helpful in that regard,²⁵
5
6 although certain types of mutations may also be difficult or impossible to detect by WES, for
7
8 example in non-coding regions.

9
10
11 From a practical perspective, the introduction of NGS into routine EB diagnostics
12
13 requires further considerations of cost, facilities, staff, and time to report. In our institution
14
15 (King's College London), current costs of WES (including bioinformatics analysis) are ~£900
16
17 (2014 prices) which compares favourably with SS of EB genes. Of note, it costs a similar
18
19 amount just to sequence the *COL7A1* gene alone. Moreover, the cost of WES is likely to
20
21 decrease further over the next few years, thus providing a strong economic argument for
22
23 adoption of NGS into EB diagnostics. The challenge, however, lies in data interrogation and
24
25 the bioinformatics analyses required to scrutinise the sequence variants and to determine
26
27 causality. For EB diagnostics this would mean a realignment of technical wet lab skills (IFM
28
29 and TEM) in favour of computer database and *in silico* work. The biggest challenge, however,
30
31 lies in the time it takes to process and analyse a case. In EB diagnostics a rapid diagnosis is
32
33 often very important to optimise clinical management, particularly in neonates with fragile
34
35 skin. The current approach using skin biopsy assessment followed by SS of candidate genes
36
37 (implicated by IFM and/or TEM) allows for possible diagnoses to be made within 2-3 days. In
38
39 contrast, the quickest time that WES could be completed (at present) would be a minimum
40
41 of 5 days. Being able to reduce the time it takes to make a diagnosis using WES, therefore,
42
43 will be fundamental to its application in clinical service. New platforms to enable this are in
44
45 development, but only when more rapid sample analysis is feasible in a diagnostic lab
46
47 setting can one really begin to think about changing diagnostic practice. For now, however,
48
49 skin biopsy remains an integral part of current EB diagnostics.
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGEMENTS

WES studies by the authors have been supported by the UK National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London, as well as DebRA UK and The Wellcome Trust. The Centre for Dermatology and Genetic Medicine in Dundee is supported by a Wellcome Trust Strategic Award (reference number 098439/Z/12/Z). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the UK Department of Health. Also, this study was supported in part by the Great Britain Sasakawa Foundation (No. 4314) and Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation (S2404) from the Japan Society for the Promotion of Science.

REFERENCES

1. Fine J-D, Bruckner-Tuderman L, Eady RA *et al*. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. *J Am Acad Dermatol* 2014; in press
2. Salam A, Proudfoot LE, McGrath JA. Inherited blistering skin diseases: underlying molecular mechanisms and emerging therapies. *Ann Med* 2014; **46**: 49-61
3. Hintner H, Stingl G, Schuler G *et al*. Immunofluorescence mapping of antigenic determinants within the dermal-epidermal junction in the mechanobullous diseases. *J Invest Dermatol* 1981; **76**: 113-118
4. Heagerty AH, Kennedy AR, Eady RA *et al*. GB3 monoclonal antibody for diagnosis of junctional epidermolysis bullosa. *Lancet* 1986; **1**: 860

- 1
2
3
4 5. Bruckner-Tuderman L, Mitsuhashi Y, Schnyder UW *et al.* Anchoring fibrils and type VII
5
6 collagen are absent from skin in severe recessive dystrophic epidermolysis bullosa. *J Invest*
7
8 *Dermatol* 1989; **93**: 3-9
- 9
10
11 6. Eady RA, Dopping-Hepenstal PJ. Transmission electron microscopy for the diagnosis of
12
13 epidermolysis bullosa. *Dermatol Clin* 2010; **28**: 211-222
- 14
15
16 7. Christiano AM, Hoffman GG, Zhang X *et al.* Strategy for identification of sequence variants
17
18 in *COL7A1* and a novel 2-bp deletion mutation in recessive dystrophic epidermolysis bullosa.
19
20 *Hum Mutat* 1997; **10**: 408-414
- 21
22
23 8. Dang N, Murrell DF. Mutation analysis and characterization of *COL7A1* mutations in
24
25 dystrophic epidermolysis bullosa. *Exp Dermatol* 2008; **17**: 553-568
- 26
27
28 9. Cho R, Simpson MA, McGrath JA. Next generation diagnostics for genodermatoses. *J*
29
30 *Invest Dermatol* 2012; **132**: E26-E27
- 31
32
33 10. Salam A, Simpson MA, Stone KL *et al.* Next generation diagnostics of heritable
34
35 connective tissue disorders. *Matrix Biol* 2013; **33C**: 35-40
- 36
37
38 11. McGrath JA, Stone KL, Begum R *et al.* Germline mutation in *EXPH5* implicates the
39
40 Rab27B effector protein Slac2-b in inherited skin fragility. *Am J Hum Genet* 2012; **91**: 1115-
41
42 1121.
- 43
44
45 12. Maddalena A, Bale S, Das S *et al.* Technical standards and guidelines: molecular genetic
46
47 testing for ultra-rare disorders. *Genet Med* 2005; **7**: 571-583
- 48
49
50 13. Richards CS, Bale S, Bellissimo DB *et al.* ACMG recommendations for standards for
51
52 interpretation and reporting of sequence variations: Revisions 2007. *Genet Med* 2008; **10**:
53
54 294-300
55
56
57
58
59
60

- 1
2
3
4 14. Biesecker LG. Exome sequencing makes medical genomics a reality. *Nat Genet* 2010; **42**:
5
6 13-14.
7
8
9
10 15. Li H, Handsaker B, Wysoker A *et al.* The Sequence Alignment/Map format and
11
12 SAMtools. *Bioinformatics* 2009; **25**: 2078-2079
13
14
15 16. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from
16
17 high-throughput sequencing data. *Nucleic Acids Res* 2010; **38**: e164
18
19
20 17. Varki R, Sadowski S, Pfendner E *et al.* Epidermolysis bullosa. I. Molecular genetics of the
21
22 junctional and hemidesmosomal variants. *J Med Genet* 2006; **43**: 641-52.
23
24
25 18. Siegel DH, Ashton GH, Penagos HG *et al.* Loss of kindlin-1, a human homolog of the
26
27 *Caenorhabditis elegans* actin-extracellular-matrix linker protein UNC-112, causes Kindler
28
29 syndrome. *Am J Hum Genet* 2003; **73**: 174-187
30
31
32 19. Techanukul T, Sethuraman G, Zlotogorski A *et al.* Novel and recurrent *FERMT1* gene
33
34 mutations in Kindler syndrome. *Acta Derm Venereol* 2011; **91**: 267-270
35
36
37 20. Fassihi H, Wessagowit V, Jones C *et al.* Neonatal diagnosis of Kindler syndrome. *J*
38
39 *Dermatol Sci* 2005; **39**: 183-185
40
41
42 21. Kern JS, Grüniger G, Imsak R *et al.* Forty-two novel COL7A1 mutations and the role of a
43
44 frequent single nucleotide polymorphism in the MMP1 promoter in modulation of disease
45
46 severity in a large European dystrophic epidermolysis bullosa cohort. *Br J Dermatol* 2009;
47
48 **161**: 1089-1097
49
50
51 22. Mellerio JE, Dunnill MG, Allison W *et al.* Recurrent mutations in the type VII collagen
52
53 gene (COL7A1) in patients with recessive dystrophic epidermolysis bullosa. *J Invest Dermatol*
54
55 1997; **109**: 246-249
56
57
58
59
60

- 1
2
3
4 23. Groves RW, Liu L, Dopping-Hepenstal PJ *et al.* A homozygous nonsense mutation within
5
6 the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1
7
8 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. *J Invest*
9
10 *Dermatol* 2010; **130**: 1551-1557
11
12
13 24. Liu L, Choy YS, Wessagowit V *et al.* Single nucleotide polymorphism in a commonly
14
15 utilized *LAMB3* primer sequence: implications for mutation detection and haplotype analysis
16
17 in junctional epidermolysis bullosa. *J Dermatol Sci* 2006; **44**: 48-51
18
19
20
21 25. Takeichi T, Nanda A, Liu L *et al.* Impact of next generation sequencing on diagnostics in a
22
23 genetic skin disease clinic. *Exp Dermatol* 2013; **22**: 825-831
24
25
26
27
28
29
30
31

32 TABLES

33
34 **Table 1.** WES data and impact on EB diagnostics for the 9 cases studied.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patient no.	Clinical diagnosis	Gene	Mutation	Mutation type	PolyPhen-2: prediction, score	SIFT: prediction, score	Inheritance	Single nucleotide substitutions in WES (number)			Impact of WES	
								Known	Novel			
								Heterozygous	Homozygous			
Case 1	GIJEB	LAMB3	c.1587_1588del2,PTC	Frameshift			AR	23488	236	256	20	Identification of an atypical mutation in LAMB3 with implications for revising genotype-phenotype correlation.
Case 2	EBS	PLEC	c.92_93insG, PTC	Frameshift			AR	24257	454	508	54	Identification of a PLEC mutation in an isoform not thought to be expressed in skin with implications for expanding PLEC gene screening for diagnostic practice
Case 3	Kindler	KIND1/FERMT1	c.1811G>A, p.Trp604* c.614G>A, p.Trp205*	Nonsense Nonsense			AR	24504	393	398	5	Improved detection of KIND1/FERMT1 mutations indicating current SS primers are sub-optimal
Case 4	Kindler	KIND1/FERMT1	c.1718+2T>C c.384_385+2del4	Splice site Splice site			AR	24283	541	553	12	Improved detection of KIND1/FERMT1 mutations indicating current SS primers are sub-optimal
Case 5	EBS/RDEB	COL7A1	c.793C>T, p.Gln265* c.6005G>A, p.Arg2002His	Nonsense Missense	Probably damaging, 1	Tolerated, 0.11	AR	23649	181	184	3	Identification of mutations in a different, unsuspected EB gene providing a diagnosis that would otherwise have been clinically erroneous and missed in SS screening
Case 6	severe RDEB	COL7A1	c.904G>T, p.Glu302* c.7505G>A, p.Gly2502Gln	Nonsense Missense	Probably damaging, 0.999	Damaging, 0	AR	24001	657	681	24	Improved detection of COL7A1 mutations in exon 98 and 99 because of previous failure to amplify DNA due to a polymorphism within one of the PCR primers used for SS
Case 7	mild RDEB	COL7A1	c.4027C>T, p.Arg1343* c.8676G>A, p.Trp2892*	Nonsense Nonsense			AR	24260	208	217	9	Improved detection of COL7A1 mutations indicating current SS primers are sub-optimal
Case 8	severe RDEB	COL7A1	c.3630_3631insC, PTC c.520G>A, p.Gly174Arg	Frameshift Missense	Probably damaging, 1	Damaging, 0.002	AR	24250	618	638	20	Improved detection of COL7A1 mutations indicating current SS primers are sub-optimal
Case 9	mild RDEB	COL7A1	c.1732C>T, p.Arg578* c.2126T>C, p.Val709Ala	Nonsense Missense	Possibly damaging, 0.939	Damaging, 0	AR	24231	207	214	7	Improved detection of COL7A1 mutations indicating current SS primers are sub-optimal

GIJEB: generalised intermediate junctional epidermolysis bullosa; EBS: Epidermolysis bullosa simplex; RDEB: recessive dystrophic epidermolysis bullosa; SS: Sanger Sequencing; PTC: premature termination codon; WES: Whole Exome Sequencing; AR: autosomal recessive.